CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan, and cetuximab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Preliminary results from a multicenter phase II trial

被引：0
|
作者：
Bennouna, J.
Faroux, R.
Francois, E.
Ligeza, C.
El Hannani, C.
Perrier, H.
Jacob, J.
Desseigne, F.
Perrocheau, G.
Douillard, J. Y.
机构：
[1] Ctr Rene Gauducheau, St Herblain, France
[2] Ctr Hosp La Roche Sur Yon, La Roche Sur Yon, France
[3] Ctr Antoine Lacassagne, Nice, France
[4] Ctr Etienne Dolet, St Nazaire, France
[5] Ctr Hosp Chateaubriand, Chateaubriand, France
[6] Hop St Joseph, Marseille, France
[7] Ctr Francois Baclesse, Caen, France
[8] Ctr Leon Berard, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4087
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Cetuximab and capecitabine as first-line treatment for elderly patients (pts) with metastatic colorectal cancer (mCRC): Preliminary results of TTD trial
    Gravalos, C.
    Rivera, F.
    Massuti, B.
    Sastre, J.
    Marcuello, E.
    Valladares, M.
    Gil, S.
    Abad, A.
    Diaz-Rubio, E.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
    Tabernero, Josep
    Van Cutsem, Eric
    Diaz-Rubio, Eduardo
    Cervantes, Andres
    Humblet, Yves
    Andre, Thierry
    Van Laethem, Jean-Luc
    Soulie, Patrick
    Casado, Esther
    Verslype, Chris
    Valera, Javier Sastre
    Tortora, Giampaolo
    Ciardiello, Fortunato
    Kisker, Oliver
    de Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5225 - 5232
  • [3] UFT/LV combination based regimens with oxaliplatin or irinotecan as first line treatment for patients (pts) with non resectable metastatic colorectal cancer(MCRC): Results of two multicentric phase II trials.
    Douillard, JY
    Bennouna, J
    Artru, P
    Perrier, H
    Paillot, B
    Husseini, F
    Priou, F
    Imadalou, K
    Delord, JP
    Bugat, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 256S - 256S
  • [4] FINAL RESULTS OF A MULTICENTRE PHASE II TRIAL EVALUATING CETUXIMAB IN COMBINATION WITH FOLFIRINOX AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Samalin, E.
    Desseigne, F.
    Thezenas, S.
    Bibeau, F.
    Viret, F.
    Mineur, L.
    Assenat, E.
    Bleuse, J.
    Portales, F.
    Crapez, E.
    Ychou, M.
    ANNALS OF ONCOLOGY, 2009, 20 : 20 - 20
  • [5] Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
    J-P Delord
    J Bennouna
    P Artru
    H Perrier
    F Husseini
    F Desseigne
    E François
    R Faroux
    D Smith
    P Piedbois
    H Naman
    J Y Douillard
    R Bugat
    British Journal of Cancer, 2007, 97 : 297 - 301
  • [6] Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI):: first-line therapy for metastatic colorectal cancer
    Delord, J-P
    Bennouna, J.
    Artru, P.
    Perrier, H.
    Husseini, F.
    Desseigne, F.
    Francois, E.
    Faroux, R.
    Smith, D.
    Piedbois, P.
    Naman, H.
    Douillard, J. Y.
    Bugat, R.
    BRITISH JOURNAL OF CANCER, 2007, 97 (03) : 297 - 301
  • [7] UFT/LV combined with oxaliplatin (TEGAFOX) or with irinotecan (TEGAFIRI) as first-line treatment for metastatic colorectal cancer patients (pts). Results of a randomized phase IIITMO study
    Bajetta, E.
    Di Bartolomeo, M.
    Ferrario, E.
    Beretta, E.
    Iacobelli, S.
    Recaldin, E.
    Pinotti, G.
    Iop, A.
    Frustaci, S.
    Cruciani, G.
    EJC SUPPLEMENTS, 2005, 3 (02): : 177 - 177
  • [8] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [9] Capecitabine (X), irinotecan (I) and bevacizumab (A) as first-line therapy for patients (PTS) with metastatic colorectal cancer (MCRC): Preliminary phase II study results
    Semir, Beslija
    Maja, Banjin
    Nadja, Paraganlija
    Timur, Ceric
    Anes, Pasic
    Berisa, Salkic
    Anes, Sosevic
    Nermina, Obralic
    ANNALS OF ONCOLOGY, 2006, 17 : 127 - 127
  • [10] PHASE II STUDY OF FIRST-LINE SUNITINIB (SU) IN COMBINATION WITH IRINOTECAN, LEUCOVORIN, AND 5-FLUOROURACIL (5-FU) (FOLFIRI) IN JAPANESE PATIENTS (PTS) WITH UNRESECTABLE/METASTATIC COLORECTAL CANCER (MCRC)
    Tsuji, A.
    Denda, T.
    Tsuji, Y.
    Satoh, T.
    Yoshida, M.
    Nishina, Y.
    Nagase, M.
    Komatsu, Y.
    Kato, T.
    Muro, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 199 - 200
12345